Cisplatin

Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness

Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness

By

Aligning chemotherapy administration to the time of day when the body is most awake benefits the effectiveness of the treatment, as shown in a mouse model.

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

By

Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.

Cisplatin-Associated Hearing Loss Is More Severe in Patients With Cockayne Syndrome

By

Although cisplatin can kill cancer, the agent also causes permanent hearing loss. The drug kills sensory cells of the inner ear, and the effects on the inner ear are likely more severe in persons with the rare form of dwarfism known as Cockayne syndrome.

Concurrent Chemoradiotherapy Using Paclitaxel Plus Cisplatin in the Treatment of Elderly Patients With Esophageal Cancer

Concurrent Chemoradiotherapy Using Paclitaxel Plus Cisplatin in the Treatment of Elderly Patients With Esophageal Cancer

The purpose of this research was to examine both efficiency and safety of concurrent chemoradiotherapy (CCRT) using paclitaxel combined with cisplatin in elderly esophageal cancer patients.

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer

This study compared the efficacy and safety of irinotecan/cisplatin and etoposide/cisplatin in first-line chemotherapy in E-SCLC.

Inherited gene variations tied to treatment-related hearing loss in cancer patients

By

Investigators linked inherited genetic variations to rapid hearing loss experienced by young cancer patients treated with the drug cisplatin.

Ipecac component enhances cisplatin in bladder cancer

By

The use of emetine dihydrochloride, an active ingredient in ipecac syrup, alone or with cisplatin therapy inhibited proliferation of bladder tumor cells in a recent study.

Chemotherapy nerve damage stops regrowth of blood stem cells

Chemotherapy-induced nerve injury in the bone marrow is what impairs the regeneration of hematopoietic stem cells, leading to anemia.

PARP inhibitors may beat cisplatin resistance in lung cancer

People with non-small cell lung cancer who become resistant to cisplatin may be able to counteract this problem with PARP inhibitors.

Epigenetic changes have a key role in chemotherapy resistance in bladder cancer

By

A new study of neoadjuvant cisplatin-based chemotherapy showed that epigenetic changes are potential key drivers in the development of chemotherapy resistance in bladder cancer.

Erlotinib doesn't hurt but doesn't help standard head-and-neck therapy

Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.

HDAC inhibitors sensitize triple-negative breast cancer cells to PARP inhibition and cisplatin

By

In vitro exposure to an HDAC inhibitor indirectly impaired the ability of triple-negative breast cancer cells to repair damaged DNA, and sensitized the cells to treatment with a PARP inhibitor and cisplatin.

PARP inhibitors may help in small cell lung cancer

PARP1 and EZH2 may be treatment targets in small cell lung cancer, based on newfound differences between this and non-small cell disease.

Radiosensitivity: A new focus on cardiovascular sequelae

Radiosensitivity: A new focus on cardiovascular sequelae

By

An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.

New marker flags DNA repair response to platinum therapy

A new marker of DNA damage may predict which triple-negative breast cancers or serous ovarian cancers will respond to platinum-based chemotherapy.

A new era in management of
 gastrointestinal cancers

A new era in management of
 gastrointestinal cancers

By

Key studies presented at the 2011 Oncology Congress focus on treatments, prevention, and early diagnosis of GI tract cancers.

Cisplatin surprise: Drug binds quickly to RNA

Cisplatin binds 20-fold more pervasively to RNA than to DNA, making RNA a potential new drug target for the platinum compound, which is used to fight tumors in nearly 70% of cancers.

Vaccine may enhance NSCLC treatment

Recent study results suggest that a targeted immunotherapy based on a poxvirus may make chemotherapy for advanced non-small cell lung cancer more effective and slow disease progression.

Combination therapy improves survival in biliary tract cancer

By

Patients with advanced biliary cancer treated with cisplatin plus gemcitabine experience a significant survival advantage without added toxicity, according to a study published in The New England Journal of Medicine (2010;362(14):1273-1281).

Chemotherapy combination effectively treats patients with endometrial cancer

By

Women with advanced or recurrent endometrial cancer respond to gemcitabine and cisplatin when used together, according to a study presented at the Society of Gynecologic Oncologists' 41st Annual Meeting.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs